Table 3 Multivariate analysis of clinicopathological tumor characteristics in entire cohort, pre and postmenopausal groups for disease free survival.

From: A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort

 

Reference

Variable

Entire cohort (N = 340)

Premenopausal groups (N = 119)

Postmenopausal groups (N = 221)

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

T size (cm)

T1

T2

1.2 (0.66–1.95)

0.673

0.67 (0.3–1.5)

0.33

1.7 (0.75–3.89)

0.65

T1

T3

1.8 (0.86–3.47)

0.128

0.73 (0.2–2.7)

0.63

3.34 (1.2–8.8)

0.016

LN status

Negative

Positive

3.75 (2.16–6.59)

0.0001

3.0 (1.3–7.5)

0.013

4.65 (2.23–9.7)

0.0001

TILs

Absent

Present

0.54 (0.00–0.83)

0.004

0.49 (0.24–1.05)

0.068

0.66 (0.38–1.2)

0.140

Subtype

HR + 

HER2 amplified

2.17 (1.33–3.55)

0.002

1.94 (0.92–4.13)

0.086

2.05 (1.06–3.99)

0.032

HR + 

TNBC

1.90 (1.1–3.27)

0.022

0.62 (0.22–1.73)

0.36

3.55 (1.84–6.83)

0.001

  1. HR hazard ratio, CI confidence interval, LN status lymph node status, TILs tumor infiltrating lymphocytes, HR + Hormone receptor positive, HER2 human epithelial growth factor receptor, TNBC triple negative breast cancer.
  2. p < 0.05, statistically significant (represented in bold).
Back to article page